BPC-157 — Body Protection Compound 157

Discovery and characterisation

BPC-157 — formally designated Body Protection Compound 157 and also known by its pharmaceutical code PL 14736 — is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The compound was first characterised in 1991 by Professor Predrag Sikiric and colleagues at the University of Zagreb, who isolated the parent sequence from human gastric juice [PMID:21548867]. The research group was investigating cytoprotective mediators naturally present in the gastric mucosa when they identified a fragment demonstrating exceptional stability and broad tissue-protective activity.

Unlike many peptides that degrade rapidly under physiological conditions, BPC-157 maintains its structural integrity across a wide pH range, including the highly acidic environment of the stomach. This acid-stability was immediately noted as pharmacologically significant and led to decades of preclinical investigation spanning gastrointestinal, musculoskeletal, cardiovascular, and neurological models [PMID:21548867]. The pentadecapeptide does not occur in isolation in nature; rather, it represents a stabilised, truncated sequence derived from a larger gastric protein, engineered to resist enzymatic degradation while retaining the cytoprotective activity of the parent molecule.

BPC-157 has a molecular weight of approximately 1,419.5 Da and is manufactured as a white lyophilised powder that is soluble in water and bacteriostatic saline.

Mechanism of action

BPC-157 exerts its effects through several overlapping signalling pathways, which collectively account for its unusually broad activity profile in preclinical research.

VEGFR2 upregulation and angiogenesis. The most consistently reported mechanism is the upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) expression [PMID:21030672]. In tendon fibroblast models, BPC-157 dose-dependently increased VEGFR2 mRNA and protein, accelerating capillary in-growth into avascular tendon tissue. This pro-angiogenic effect is considered central to its wound-healing and tissue-repair activity: new vasculature supplies oxygen and growth factors that sustain cellular repair processes.

Nitric oxide (NO) system modulation. BPC-157 appears to act as a modulator — rather than a simple stimulator — of nitric oxide synthase (NOS) activity. Research demonstrates that it can both rescue NOS-inhibited models and attenuate excessive NO production in inflammatory states [PMID:21548867]. This bidirectional regulation suggests interaction upstream of NOS itself, possibly at the level of eNOS transcription or cofactor availability.

Growth hormone receptor sensitisation. Evidence from gastric ulcer models indicates that BPC-157 does not raise circulating GH levels directly but instead upregulates GH receptor expression in peripheral target tissues [PMID:21548867]. This sensitisation mechanism may partly explain musculoskeletal effects that superficially resemble GH administration.

Dopaminergic and serotonergic stabilisation. In the central nervous system, BPC-157 modulates the dopamine and serotonin systems. Animal studies demonstrate normalisation of dopamine depletion following haloperidol challenge, and attenuation of dopamine-related catalepsy [PMID:11080531]. This neurotrophic-like activity distinguishes BPC-157 from simple cytoprotective peptides and has motivated research into traumatic brain injury and depression models [PMID:27012953].

FAK pathway and cell migration. Chang et al. demonstrated that BPC-157 activates focal adhesion kinase (FAK) and paxillin in tendon fibroblasts, promoting directed cell migration — a prerequisite for organised tissue repair [PMID:21030672]. This effect was blocked by VEGFR2 inhibition, confirming the upstream role of the VEGF axis in BPC-157-driven cellular responses.

Researched applications

The breadth of preclinical literature covering BPC-157 is unusual for a single compound and reflects the downstream consequences of its angiogenic and NO-modulating properties across tissue types.

Gastrointestinal protection and repair. The original therapeutic rationale centred on gastric mucosa. BPC-157 accelerates healing of gastric ulcers, oesophageal lesions, and colon anastomoses in rodent models, even when administered orally — consistent with its acid-stability [PMID:21548867]. It has also been studied in inflammatory bowel disease models, where it reduces colonic inflammation and promotes mucosal restitution.

Tendon and ligament healing. Krivic et al. demonstrated that BPC-157 significantly improved tendon-to-bone healing in Achilles detachment models, reversing the inhibitory effect of corticosteroid co-administration [PMID:16583453]. Chang et al. showed enhanced tendon outgrowth and fibroblast survival in vitro [PMID:21030672]. Cerovecki et al. extended these findings to medial collateral ligament transection in rats, reporting faster histological maturation and greater biomechanical strength at the repair site compared with vehicle controls [PMID:20225288].

Muscle repair. Pevec et al. studied skeletal muscle healing under conditions of systemic corticosteroid impairment, finding that BPC-157 restored normal healing trajectories in both treated and untreated animals [PMID:20190676]. The mechanism was attributed to preservation of satellite cell activity and local angiogenesis.

Cardiac and ischaemia-reperfusion injury. Rodent models of coronary artery occlusion have found reduced infarct size and improved functional recovery with BPC-157 pre- and post-treatment, effects proposed to operate through eNOS upregulation and mitochondrial preservation [PMID:21548867].

Neurological injury and behaviour. Brain-gut axis research from the Zagreb group describes neuroprotective outcomes in traumatic brain injury models and antidepressant-like effects in Porsolt forced-swim tests [PMID:11080531][PMID:27012953]. These findings position BPC-157 as a peptide of interest in neurotrauma and mood-disorder research.

Dosing range across published studies

It is critical to note that no human clinical trials establishing safe or effective doses of BPC-157 have been completed and published. All dosing data below derive exclusively from preclinical animal studies and should be understood in that context.

In rodent models, the most frequently studied parenteral dose range is 10–10 µg/kg to 10 µg/kg body weight, typically administered subcutaneously or intraperitoneally once or twice daily [PMID:21030672][PMID:16583453]. Translating these figures to common human-equivalent research benchmarks (using the FDA body surface area conversion) produces approximate ranges of 250–500 µg per administration, which is the dose range most cited in researcher discussions. Oral dosing studies in gut-pathology models have used similar absolute amounts — approximately 500 µg per day in divided doses — capitalising on the compound's acid resistance [PMID:21548867]. Study durations in published literature range from 7 days (acute injury models) to 8 weeks (chronic tendon and ligament studies). Dose escalation beyond this range has not demonstrated proportionate benefit in the available literature and has not been systematically studied for safety at supratherapeutic levels.

Safety profile

Within the published preclinical literature, BPC-157 displays a notably favourable tolerability profile. Acute and sub-chronic toxicity studies in rodents have not identified organ toxicity, haematological abnormalities, or deaths attributable to the compound at standard research doses [PMID:21548867]. No mutagenicity or genotoxicity signals have emerged from in vitro assays conducted by the Zagreb research group.

The most commonly reported adverse event in animal models is transient local reaction at the subcutaneous injection site — mild erythema or swelling that resolves within 24 hours without intervention. This is consistent with the physicochemical properties of the peptide rather than any pharmacological toxicity.

A theoretical safety concern arising from BPC-157's pro-angiogenic mechanism is the potential for accelerated tumour vascularisation in subjects with pre-existing malignancy. VEGFR2 upregulation is a pathway exploited by several oncology targets in the opposite direction (anti-VEGF therapy), and preclinical evidence does not exclude this risk. For this reason, researchers consistently exclude animals with malignant pathology from BPC-157 studies. This theoretical contraindication is considered the most clinically relevant precaution.

No human safety data exist. The compound has not completed Phase I clinical evaluation in any jurisdiction.

UK regulatory status 2026

BPC-157 is not approved as a medicinal product by the Medicines and Healthcare products Regulatory Agency (MHRA). It has no Marketing Authorisation, Investigational Medicinal Product Dossier approval, or recognised veterinary licence in the United Kingdom. It therefore cannot be lawfully sold, supplied, or administered to humans or animals for therapeutic purposes under the Human Medicines Regulations 2012.

In vitro laboratory research use — where the compound is handled within a controlled laboratory environment and not administered to humans or animals — falls outside the scope of the Human Medicines Regulations. Accordingly, researchers conducting cell-based or tissue-based in vitro studies in accredited laboratory settings may handle BPC-157 as a research chemical, provided the material is sourced from a compliant supplier and used strictly within research protocols.

The MHRA has indicated that its enforcement priorities target suppliers and practitioners who promote peptides for human use, rather than academic research contexts. Nonetheless, all acquisition and handling should be documented in accordance with institutional governance requirements.

Reconstitution and storage

Lyophilised BPC-157 is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol) at a standard concentration of 1 mg/mL. The vial should be swirled gently — not shaken — to avoid peptide aggregation. Reconstituted solution stored at 2–8°C in a sealed, light-protected vial retains reported stability for approximately 28–30 days. For longer-term archiving, researchers aliquot the reconstituted solution into single-use volumes, which are then stored at -20°C and thawed once immediately before use; repeated freeze-thaw cycles are avoided as they increase the risk of peptide degradation. Lyophilised powder, unopened and kept desiccated below 25°C away from light, maintains integrity for 24 months or the period specified by the supplier.

Frequently asked research questions

Is BPC-157 the same as PL 14736? Yes. PL 14736 is the pharmaceutical development code assigned during early formulation work; both designations refer to the identical 15-amino-acid sequence.

Does BPC-157 require refrigeration before reconstitution? The lyophilised powder is stable at room temperature short-term, but long-term archiving below 25°C and away from moisture is recommended by manufacturers. Once reconstituted, refrigeration at 2–8°C is required.

Is oral administration as effective as subcutaneous in research models? For gastrointestinal endpoints, oral delivery appears similarly effective in published rodent studies owing to acid stability. For systemic musculoskeletal endpoints, subcutaneous administration has been the predominant route in positive studies, and direct comparison data are limited.

Does BPC-157 interact with NSAIDs or corticosteroids? Preclinical data suggest BPC-157 partially counteracts the wound-healing impairment associated with systemic corticosteroids [PMID:20190676], which is why several studies deliberately include corticosteroid co-administration as a stress model. Formal pharmacokinetic interaction studies with NSAIDs have not been published.

How does BPC-157 differ from TB-500 (Thymosin Beta-4)? TB-500 primarily acts through actin polymerisation modulation and is a fragment of the endogenous protein Thymosin Beta-4, whereas BPC-157 originates from gastric protein and signals primarily through VEGFR2 and the NO system. The two are often studied in combination for putative complementary angiogenic and cytoskeletal effects.

---

BPC-157 appears in the following research stacks on this site: BPC-157 + TB-500 Healing Stack, BPC-157 + TB-500 + GHK-Cu Advanced Recovery, BPC-157 + KPV + Thymosin Alpha-1 Immune Stack, BPC-157 + GHK-Cu Hair Growth Stack, TB-500 + BPC-157 Tendon Repair Stack, Ipamorelin + CJC-1295 + BPC-157 Recomp Stack.

Source research-grade BPC-157

BPC-157 — Body Protection Compound 157 is sold for laboratory and in vitro research use only. UK regulatory status: Unapproved research compound in UK (MHRA), US (FDA) and EU (EMA). For in vitro laboratory research only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

1. Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16) :1612-32 doi:10.2174/138161211796196954 · PMID: 21548867
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH.. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3) :774-780 doi:10.1152/japplphysiol.00945.2010 · PMID: 21030672
3. Pevec D, Novinscak T, Brcic L, et al.. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor. 2010;16(3) :BR81-88 · PMID: 20190676
4. Krivic A, Anic T, Sikiric P, et al.. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5) :982-989 doi:10.1002/jor.20083 · PMID: 16583453
5. Cerovecki T, Bojanic I, Brcic L, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9) :1155-1161 doi:10.1002/jor.21107 · PMID: 20225288
6. Sikiric P, Separovic J, Buljat G, et al.. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. Journal of Physiology. 2000;94(2) :99-107 doi:10.1016/S0928-4257(00)00149-0 · PMID: 11080531
7. Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8) :857-865 doi:10.2174/1570159X13666160502153012 · PMID: 27012953